Distrofia muscular de Duchenne é uma desordem neuromuscular causada pela mutação ou deleção do gene da distrofina, a qual é ligada ao cromossomo X. Estudos recentes têm demonstrado o importante papel da distrofina no SNC, sendo sua deficiência relacionada com uma variedade de anormalidades na função do SNC, como comportamento e disfunção cognitiva. Os modelos animais mais adequados para esses estudos são os que apresentam o quadro clinico mais semelhante ao da DMD encontrada em humanos, como cães Golden Retriever com distrofia muscular (GRMD). Por não haver ainda estudos a respeito do SNC de animais GRMD, o objetivo deste trabalho foi analisar a morfologia do encéfalo dos GRMD e o de animais não distróficos, através de análise macroscópica, utilizando métodos de medição e registro fotográfico, e análise microscópica, utilizando a técnica de coloração de violeta cresil modificada. Entretanto, usando a metodologia proposta, não foi possível verificar diferenças significativas no encéfalo quando comparados os animais distróficos e os não distróficos, o que está em concordância com a literatura para a DMD usando os mesmos parâmetros. Em tempo, existe uma variação individual na morfologia do encéfalo do cão, independente de serem animais do grupo de distróficos ou controles. Outras técnicas devem ser aplicadas a fim de elucidar as consequências da ausência total ou parcial da distrofina no SNC / Duchenne muscular dystrophy is a neuromuscular disorder caused by the mutation or deletion of the dystrophin gene, which is linked to chromosome X. Recent studies have shown the important role of dystrophin in the CNS, and its related defect with a variety of abnormalities in the function of CNS, such as behavior and cognitive dysfunction. The most suitable animals models for these studies are those with the most similar clinical picture to DMD found in humans, as Golden Retriever dogs with muscular dystrophy (GRMD). There are no further studies on the GRMD animal CNS, and the aim of this study was to analyze the morphology of the brain of GRMD and not dystrophic animals through macroscopic analysis using measurement and photographic registration methods, and microscopic analysis using the modified cresyl violet staining technique. However, using the proposed methodology, we could not find significant differences in the brain when comparing the dystrophic animals and non-dystrophic, which is in agreement with the literature for DMD using the same parameters. In time, there is individual variation in dog brain morphology, whether they are animals of the dystrophic group or controls. Other techniques should be applied in order to elucidate the consequences of the total or partial absence of dystrophin in the CNS

L'objectif de ce travail est de développer la partie clinique de la banque de données du gène DMD, afin d'étudier l'histoire naturelle des dystrophinopathies et les corrélations génotype–phénotype, et de faciliter la sélection des patients pour les futurs essais thérapeutiques. La méthodologie créée pour le gène DMD peut être généralisée et utilisée pour d'autres banques de données dédiées à des maladies génétiques. La collecte de 70 000 données cliniques chez 600 patients avec un suivi longitudinal moyen de 12 ans permet de décrire l'histoire naturelle des dystrophies musculaires de Duchenne et de Becker et des formes symptomatiques chez les femmes. Nous avons pu préciser l'hétérogénéité phénotypique sur le plan moteur, orthopédique et respiratoire (forme sévère et forme intermédiaire de la dystrophie musculaire de Duchenne), sur le plan cardiaque (absence de corrélation entre les atteintes motrice et cardiaque, variabilité de l'atteinte cardiaque), et sur le plan cérébral (atteinte intellectuelle chez les patients avec dystrophie musculaire de Becker, troubles psychologiques des dystrophinopathies). L'utilisation de cet outil par les cliniciens et les généticiens devrait faciliter le travail de recherche clinique et la réalisation des futurs essais cliniques. Ceci nécessite maintenant de développer l'accessibilité de la banque de données et d'envisager sa pérennisation. / The objective of this work is to develop the clinical part of the French dystrophinopathy data-base, in order to study the natural history and the genotype-phenotype correlations, and to facilitate the selection of the patients for the future therapeutic trials. The methodology developed for the DMD gene can be generalized and used for the other databases dedicated to genetic diseases. The collection of 70 000 clinical data for 600 patients with an average lon-gitudinal follow-up of 12 years allows to clarify the natural history of the muscular dystrophies of Duchenne and Becker and in symptomatic females. We were able to specify the pheno-typic heterogeneity of the motor, orthopaedic and respiratory involvements (severe form and intermediary form of the Duchenne muscular dystrophy), of the cardiac disorder (absence of correlation between motor and cardiac involvements, variability of the cardiomyopathy), and of the brain function (mental deficiency in the patients with Becker muscular dystrophy, psychological disorders in dystrophinopathies). The use of this tool by the clinicians and the ge-neticists should facilitate their clinical research work and the realization of the future clinical trials. This requires now to develop the accessibility of the database and to ensure its continued existence.

No description available.

<p>Duchenne muscular dystrophy (DMD) is a severe hereditary disorder caused by a loss of dystrophin, an essential musculoskeletal protein. Decades of promising research have yielded only modest gains in survival and quality of life for these patients and there have been no approved gene therapies for DMD to date. There are two significant hurdles to creating effective gene therapies for DMD; it is difficult to deliver a replacement dystrophin gene due to its large size and current strategies to restore the native dystrophin gene likely require life-long administration of a gene-modifying drug. This thesis presents a novel method to address these challenges through restoring dystrophin expression by genetically correcting the native dystrophin gene using engineered nucleases that target one or more exons in a mutational hotspot in exons 45-55 of the dystrophin gene. Importantly, this hotspot mutational region collectively represents approximately 62% of all DMD mutations. In this work, we utilize various engineered nuclease platforms to create genetic modifications that can correct a variety of DMD patient mutations.</p><p>Initially, we demonstrate that genome editing can efficiently correct the dystrophin reading frame and restore protein expression by introducing micro-frameshifts in exon 51, which is adjacent to a hotspot mutational region in the dystrophin gene. Transcription activator-like effector nucleases (TALENs) were engineered to mediate highly efficient gene editing after introducing a single TALEN pair targeted to exon 51 of the dystrophin gene. This led to restoration of dystrophin protein expression in cells from DMD patients, including skeletal myoblasts and dermal fibroblasts that were reprogrammed to the myogenic lineage by MyoD. We show that our engineered TALENs have minimal cytotoxicity and exome sequencing of cells with targeted modifications of the dystrophin locus showed no TALEN-mediated off-target changes to the protein coding regions of the genome, as predicted by in silico target site analysis. </p><p>In an alternative approach, we capitalized on the recent advances in genome editing to generate permanent exclusion of exons by using zinc-finger nucleases (ZFNs) to selectively remove sequences important in specific exon recognition. This strategy has the advantage of creating predictable frame restoration and protein expression, although it relies on simultaneous nuclease activity to generate genomic deletions. ZFNs were designed to remove essential splicing sequences in exon 51 of the dystrophin gene and thereby exclude exon 51 from the resulting dystrophin transcript, a method that can potentially restore the dystrophin reading frame in up to 13% of DMD patients. Nucleases were assembled by extended modular assembly and context-dependent assembly methods and screened for activity in human cells. Selected ZFNs had moderate observable cytotoxicity and one ZFN showed off-target activity at two chromosomal loci. Two active ZFN pairs flanking the exon 51 splice acceptor site were transfected into DMD patient cells and a clonal population was isolated with this region deleted from the genome. Deletion of the genomic sequence containing the splice acceptor resulted in the loss of exon 51 from the dystrophin mRNA transcript and restoration of dystrophin expression in vitro. Furthermore, transplantation of corrected cells into the hind limb of immunodeficient mice resulted in efficient human dystrophin expression localized to the sarcolemma. </p><p>Finally, we exploited the increased versatility, efficiency, and multiplexing capabilities of the CRISPR/Cas9 system to enable a variety of otherwise challenging gene correction strategies for DMD. Single or multiplexed sgRNAs were designed to restore the dystrophin reading frame by targeting the mutational hotspot at exons 45-55 and introducing either intraexonic small insertions and deletions, or large deletions of one or more exons. Significantly, we generated a large deletion of 336 kb across the entire exon 45-55 region that is applicable to correction of approximately 62% of DMD patient mutations. We show that, for selected sgRNAs, CRISPR/Cas9 gene editing displays minimal cytotoxicity and limited aberrant mutagenesis at off-target chromosomal loci. Following treatment with Cas9 nuclease and one or more sgRNAs, dystrophin expression was restored in Duchenne patient muscle cells in vitro. Human dystrophin was detected in vivo following transplantation of genetically corrected patient cells into immunodeficient mice. </p><p>In summary, the objective of this work was to develop methods to genetically correct the native dystrophin as a potential therapy for DMD. These studies integrate the rapid advances in gene editing technologies to create targeted frameshifts that restore the dystrophin gene around patient mutations in non-essential coding regions. Collectively, this thesis presents several gene editing methods that can correct patient mutations by modification of specific exons or by deletion of one or more exons that results in restoration of the dystrophin reading frame. Importantly, the gene correction methods described here are compatible with leading cell-based therapies and in vivo gene delivery strategies for DMD, providing an avenue towards a cure for this devastating disease.</p> / Dissertation

Les subtélomères forment la transition entre les séquences spécifiques des chromosomes et les répétitions télomériques terminales. Ils semblent capables d’influencer les fonctions télomériques mais les connaissances sur les mécanismes mis en jeu sont encore limitées. Les subtélomères sont pourtant associés à de nombreuses pathologies comme la myopathie facio-scapulo-humérale (FSHD), une dystrophie musculaire secondaire à la contraction de répétitions macrosatellites D4Z4 dans la région subtélomérique 4q35. Afin d’étudier les propriétés de la séquence subtélomérique D4Z4, nous avons créé des constructions reproduisant l’organisation génomique au locus 4q35. Nous avons montré que D4Z4 est capable d’adresser un télomère à la périphérie du noyau. Cette activité est couplée à une activité insulatrice au niveau d’une séquence proximale de 80 pb et est dépendante de CTCF et des Lamines A. De plus, la relocalisation périphérique d’un télomère par D4Z4 s’accompagne d’une réplication plus tardive de celui-ci. Par ailleurs, la recherche de séquences capables de s’opposer à l’effet de position télomérique (TPE) a identifié un élément de 30 pb contenant un site CTCF dans la séquence insulatrice proximale de D4Z4. De même,   l’introduction d’un signal de poly-adénylation entre un gène rapporteur et les répétitions télomériques interfère avec le TPE et est accompagnée d’une diminution d’un transcrit hybride contenant le gène rapporteur et des répétitions télomériques, suggérant un rôle des transcrits télomériques TERRAs dans la régulation du TPE. En conclusion, ce travail a permis de caractériser l’implication de séquences subtélomériques, et notamment D4Z4, dans la régulation des télomères, leur compartimentalisation nucléaire, la réplication ou l’effet de position télomérique. De plus, il apporte un éclairage nouveau sur la physiopathologie de la FSHD et ouvre des perspectives dans la compréhension d’autres pathologies liées aux subtélomères. / Subtelomeres form the transition between chromosome specific sequences and terminal telomeric repeats. They might influence telomeric functions but underlying mechanisms are still unclear. Nevertheless, subtelomeres are associated with a number of human pathologies such as facioscapulohumeral muscular dystrophy (FSHD), an autosomal dominant disease secondary to the contraction of an array of D4Z4 macrosatellite repeats in the subtelomeric region 4q35. In order to study the biological function of the D4Z4 sequence, we created contructs that mimic the genomic organization of the 4q35 locus. We showed that D4Z4 is able to localize a telomere at the nuclear periphery. This perinuclear activity was dependant on interactions with CTCF and A type lamins and lied within a 80 bp proximal sequence that harbors an insulator activity. Moreover, the peripheral positionning of a telomere by D4Z4 is accompanied by a late replication timing of the telomere. We also searched for sequences able to counteract telomeric position effect (TPE) and identified a 30 bp element containing a CTCF binding site in the proximal region of D4Z4. In another construct, the introduction of a poly-adenylation signal between a reporter gene and telomeric repeats counteracted TPE. This effect is accompanied by the production of a hybrid transcript encompassing the reporter gene and telomeric repeats, suggesting a role for the TERRAs telomeric transcripts in TPE regulation. This work contibuted to characterize the role of subtelomeric sequences, especially the D4Z4 macrosatellite, in telomere regulation, their nuclear compartimentalization, their replication or the telomeric position effect. We will discuss the implications in the understanding of the pathophysiology of FSHD and other subtelomeric diseases.

Duchenne muscular dystrophy (DMD) is a fatal, muscle-wasting disorder due to mutations/deletions in the dystrophin gene. Whilst improvements in palliative care have increased the life expectancy of patients, cardiomyopathy and respiratory complications are still the leading causes of death. A potential therapy for the treatment of DMD is antisense oligonucleotides (AOs), which modulate dystrophin pre-mRNA splicing to restore the dystrophin reading frame and generate a truncated functional protein. Conjugation of AOs to cell penetrating peptides (CPP), such as Pip5e-, significantly improves delivery to skeletal muscles and to the heart, which is imperative given the impact of cardiomyopathy to mortality. However, it should be noted that the contribution of skeletal muscles, such as the core respiratory muscle, the diaphragm, in dystrophic cardiopulmonary function is poorly understood. The specific aims of the work in this thesis were to (i) understand the effect of the diaphragm on cardiac function using magnetic resonance imaging (MRI), (ii) screen a number of derivatives of Pip5e (Pip6) in an effort to discover further promising peptides and define the properties integral to heart penetrating capacity, and (iii) assess whether Pip6-PMOs restore cardiac function (MRI) following a repeat, low dose regimen. In short, the specific restoration of dystrophin in the diaphragm of the dystrophic mouse model, the mdx mouse, did not improve cardiac function, highlighting the importance of a body-wide therapy. The screening of multiple Pip5e-PMO derivatives revealed 3 promising peptides with improved cardiac splicing capacity; however, serial deletions of amino acids from the central core resulted in the diminution of dystrophin restoration, possibly due to a reduction in hydrophobicity. Finally, the Pip6-PMO treatment regimen substantially restored dystrophin protein (28% in heart) and stabilised cardiac function, even with an increased work load. In conclusion, this study illustrates the importance of a body-wide treatment, such as the CPP strategy (Pip-PMO). These Pip-PMO conjugates demonstrate high dystrophin restoration in a number of muscles, including cardiac muscle, and have a beneficial effect on cardiac function.

La dystrophie facioscapulohumérale (FSHD) est une dystrophie musculaire autosomique dominante, dégénérative et progressive. Les traitements élaborés jusqu'à présent n'ont pas réussi à améliorer le quotidien des patients FSHD. Plusieurs études se sont focalisées sur les mécanismes moléculaires de cette pathologie, néanmoins plusieurs d'entre elles sont contradictoires. La vision actuelle de la FSHD est celle d'une pathologie due à un mécanisme épigénétique complexe et les mécanismes moléculaires responsables de cette pathologie sont encore mal connus. Plusieurs analyses comparatives des profils d'expression des ARNm et des protéines de muscles de patients atteints de FSHD et de contrôles ont permis de montrer que plusieurs gènes impliqués dans le stress oxydant sont dérégulés de façon spécifique dans les muscles FSHD. Nos travaux ont permis de montrer dans la FSHD, aussi bien au niveau systémique, musculaire et cellulaire (cultures primaires musculaires) une augmentation des dommages oxydatifs qui se traduisent par une augmentation des peroxydes lipidiques et protéines oxydées, associés à une altération des défenses antioxydantes. Ce stress oxydant dans les biopsies musculaires et cultures primaires musculaires est associé à un dysfonctionnement mitochondrial. Des analyses plus fines sur l'action des espèces réactives de l'oxygène et leurs sources pourraient contribuer à une meilleure compréhension des bases physiopathologiques de la FSHD et permettre la sélection de thérapeutiques adaptées aux anomalies des patients FSHD. / Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal inherited muscular dystrophy. Actually no treatment led to improve the quality of life. Many studies have been focused on the molecular mechanisms of this disease, several of them were contradictory. The present view of the FSHD seems to be due to a complex epigenetic mechanism. Actually, no gene has been identified. Several comparative studies permit the identification of many genes involved in oxidative stress, deregulated in FSHD myoblasts and biopsies in comparison to healthy ones. Analysis of oxidative stress markers show that patients with FSHD present increased oxidative damage in blood as well as in biopsy muscle and muscular primary cell culture associated with altered antioxidant enzyme defenses. Oxidative stress is also associated with mitochondrial dysfunction. Complementary studies focusing in pathway of reactive oxygen species would contribute to a better understanding of pathophysiological bases of FSHD in order to establish a very helpful therapeutics for FSHD patients.

Title: The effect of analytic and synthetic methods in patients with muscular dystrophy Objectives: Two main objectives are set in my thesis. The first objective is to summarize the theoretical knowledge concerning problems of muscular dystrophy, its classification, hereditary predispositions, diagnostic procedures, subsequent care and to present international grant projects, and the muscular dystrophy world organization and registry. The second objective is to assess the effect of the six months lasting physiotherapeutic intervention on the self-sufficiency and self-reliance of given probands - the individuals suffering from the muscular dystrophy at the age from 40 to 66 years, and to assess the extent of muscular shortening according to Janda in the experimental group Methods: This thesis is of an exploratory nature. It is an experimental study focused on the assessment of the effect of the physiotherapeutic intervention in the individuals suffering from the muscular dystrophy. To assess the extent of the improvement I used the information collected during the kinesiologic analyses (entry, final, follow up) that included goniometric assessment according to Janda, the examination of shortened muscles according to Janda, the examination of joint play according to Lewit and Rychlíková, the examination of...

A forma mais comum de distrofia muscular em humanos é do tipo Duchenne, com uma incidência aproximada de um caso a cada 3.500 nascimentos masculinos. A Distrofia Muscular do Golden Retriever (DMGR) é considerada o modelo animal mais apropriado à Distrofia Muscular de Duchenne (DMD). A Densitometria Óptica Radiográfica é um método de análise para quantificação da matéria mineral óssea, sendo, neste estudo, realizado com radiografias simples da tíbia direita ao lado de escala de alumínio. Foram utilizados 15 cães da raça Golden Retriever, sendo 5 cães normais, 5 fêmeas portadoras e 5 machos afetados pela DMGR, que foram radiografados mensalmente, dos 3 aos 9 meses de idade. Estas radiografias foram digitalizadas e analisadas por meio de um software de análise de imagens (ImageLab, Softium®), que compara as tonalidades de cinza da escala com região óssea analisada, obtendo-se valores em milímetros de alumínio (mmAl). Os resultados obtidos foram analisados estatisticamente utilizando o procedimento Proc Means do programa Statistical Analysis System, versão 8.0. O estudo revelou que a região epifisária possui maior densidade mineral óssea (DMO), seguida pela região metafisária e diafisária, respectivamente, nos três grupos avaliados, ao longo do período experimental, e seguiram o comportamento do peso corpóreo. Houve uma tendência de aumento da DMO nas três regiões avaliadas dos três grupos ao longo do experimento. A região metafisária proximal de tíbia demonstrou ser a região de eleição para a leitura da DMO por ser o local estudado com menor correlação com o peso corpóreo e por promover estimativas médias consideradas significativas entre grupos avaliados mais cedo que nas demais regiões O potencial de diagnóstico do exame densitométrico, em relação a DMGR, foi considerado baixo, entretanto demonstrou ter grande potencial no acompanhamento do progresso desta doença por apresentar alta sensibilidade para detecção de variações na densidade mineral óssea. / Duchenne Muscular Dystrophy is the most common type of muscular dystrophy in humans affecting 1 in 3,500 male births. Muscular dystrophy in Golden Retrievers appears to be an appropiate model of the human Duchenne Muscular Dystrophy. Radiographic Optical Densitometry is an analitic method to meansure bone mineral content. This technique was performed by right tíbia simple radiograph conjugated with an aluminium stepwedge. 5 helthy dogs, 5 female carriers and 5 male affected dogs by Golden Retriever Muscular Dystrophy were divided in 3 groups. Monthly, all the dogs were radiographed from 3-mouths until 9-mouths old. Radiographs were digitalized and analyzed by an image processing software (ImageLab, Softium), which compares the aluminium grey scale tonalities with a bone region analyzed obtaining with this the value of bone mineral density in aluminium milimeters (mmAl). The obtained results were statistically analyzed using the the procedure Proc Means of the program Statistical Analysis System 8.0 software. The epifisary region possess higher bone mineral density followed for the metafisary and diafisary regions, respectively, in the three evaluated groups during the experimental period and followed by the behavior of the corporeal weight. There was a trend of increase of the bone mineral density in the three evaluated regions of all three groups. The proximal metafisary region of tíbia demonstrated to be the best region of selection to evaluate the bone mineral density since it is place studied with less correlation with the corporeal weight and by promoting significant considered average estimates between groups evaluated earlier than other regions. The potential of diagnosis of this densitometric method in Golden Retriever Muscular Dystrophy was considered low, however this study demonstrated to have great potential in the accompanying the progress of this disease due to the high sensitivity for detection of bone mineral density changes.

A distrofia muscular dos cães Golden Retriever (GRMD), uma miopatia degenerativa causada pela ausência da distrofina é geneticamente homóloga a distrofia muscular de Duchenne que acomete humanos, portanto, estes cães são considerados modelos experimentais para estudos em terapia celular. Seu sucesso depende da imunossupressão adequada. A ciclosporina A (CsA) é indicada para tal, a monitorização de suas concentrações sangüíneas e efeitos adversos são essenciais para viabilizar a terapia. Foram estudados cães GRMD, e normais da mesma raça, submetidos a terapia com CsA, associada, nos GRMD, ao transplante. Foram avaliados as concentrações sangüíneas do fármaco e seus possíveis efeitos sobre as funções renal e hepática sendo consideradas as manifestações clínicas relacionadas, urinálise, hemograma, testes de função glomerular, e concentrações séricas de uréia, creatinina, alanina amino transferase (ALT), fosfatase alcalina (FA), cálcio, fósforo, sódio e potássio. Como resultados houve aumento discreto na uréia sérica de ambos os grupos; reações adversas como vômito, diarréia, tricose, periodontite e gengivite; diminuição dos níveis de ALT, cilindrúria e proteinúria e aumento da densidade urinária no grupo dos GRMD. As concentrações séricas de CsA oscilaram muito, em seis dos oito animais. Concluímos que maiores estudos devem ser realizados quanto à função renal dos GRMD e que as doses variam individualmente sendo de maior importância avaliar a concentração do fármaco no sangue e sua viabilização no uso da terapia celular. / The muscular dystrophy of Golden Retriever (GRMD) is a degenerative miopaty caused by the absence of dystrophy and it is genetically homologue of the Duchenne muscular dystrophy in humans, so, these dogs are considerably experimental models for studies on cellular therapy. Their successful depends of the adequate immunosuppression. Cyclosporin A (CsA) is indicated for that, the monitoring of the blood concentration and adverse effects are essential to viabilise the therapy. It was studied GRMD dogs, and normal dogs from the same breed, submitted for therapy with CsA, associated, on GRMD, of cell transplantation. It was evaluated blood concentration of the drug, and their possible effects on renal and hepatic functions has been considerate the clinic manifestations, urinalisis, blood counts, testis of glomerular function and blood concentrations of urea, cretinine, alanine aminotransferase, alkaline fosfatase, calcium, phosphorus, sodium and potassium. In our results we found a discrete increase of blood urea on booth groups; adverse reactions like vomits, diarrhea, tricose, periodontitis and gingivitis; decrease of blood alanine aminotransferase, increased levels of urine?s cylinders and protein and also increase of urinary density on GRMD group. The CsA blood concentrations oscillated too much on six than eight of our animals. We concluded that more researches wants to be done to evaluated renal functions of GRMD dogs and also that the doses varieties individually and the correct dosage as to important as the evaluation of the blood concentration of the drug and became viable for cell therapy.